Affimed is building a mature pipeline of unique therapeutic antibodies for partnership following preclinical or clinical proof of concept studies.
At Affimed, we are focused on developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and inflammatory diseases. Collaborating with leading biopharmaceutical companies is a cornerstone of Affimed´s business strategy. With our proprietary TandAb® technology, Affimed generated the next generation of therapeutic antibodies.
Affimed plans to form partnerships based on its proprietary TandAb® platform and its product portfolio. Up to now Affimed has successfully generated more than 20 antibody candidates against cancer targets. In order to address new targets, Affimed has access to fully human antibody libraries which are screened by phage and yeast display.
Partnering deals and strategic alliances based on our product candidates or on our TandAb® technology platform comprising RECRUIT-TandAbs®, PROLONG-TandAbs® and BiBLOCK-TandAbs® offer our partners a strongly competitive and versatile collaboration.